Nothing Special   »   [go: up one dir, main page]

BRPI0907469B8 - composição farmacêutica - Google Patents

composição farmacêutica

Info

Publication number
BRPI0907469B8
BRPI0907469B8 BRPI0907469A BRPI0907469A BRPI0907469B8 BR PI0907469 B8 BRPI0907469 B8 BR PI0907469B8 BR PI0907469 A BRPI0907469 A BR PI0907469A BR PI0907469 A BRPI0907469 A BR PI0907469A BR PI0907469 B8 BRPI0907469 B8 BR PI0907469B8
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
tissue regeneration
tissue
compositions
target
Prior art date
Application number
BRPI0907469A
Other languages
English (en)
Inventor
Maria Chudzinski-Tavassi Ana
De Souza Ventura Janaina
Christian Carrijo Carvalho Linda
Original Assignee
Ana Marisa Chudzinski Tavassi
Biolab Sanus Farmaceutica Ltda
Fund De Amparo A Pesquisa Do Estado De Sao Paulo Fapesp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ana Marisa Chudzinski Tavassi, Biolab Sanus Farmaceutica Ltda, Fund De Amparo A Pesquisa Do Estado De Sao Paulo Fapesp filed Critical Ana Marisa Chudzinski Tavassi
Publication of BRPI0907469B1 publication Critical patent/BRPI0907469B1/pt
Publication of BRPI0907469B8 publication Critical patent/BRPI0907469B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/6408—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

peptídeo isolado e seu uso, composição farmacêutica, método para reduzir morte celular e degeneração tecidual, método para regeneração tecidual em um alvo e método para curar ferimento. são descritas, composições para regeneração de tecido e reparo de ferimento, dentre outras aplicações.
BRPI0907469A 2008-01-22 2009-01-22 composição farmacêutica BRPI0907469B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2274708P 2008-01-22 2008-01-22
PCT/IB2009/050237 WO2009093189A2 (en) 2008-01-22 2009-01-22 Peptides, compositions, and uses thereof

Publications (2)

Publication Number Publication Date
BRPI0907469B1 BRPI0907469B1 (pt) 2019-10-29
BRPI0907469B8 true BRPI0907469B8 (pt) 2021-05-25

Family

ID=40765727

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0907469A BRPI0907469B8 (pt) 2008-01-22 2009-01-22 composição farmacêutica

Country Status (11)

Country Link
US (1) US8883740B2 (pt)
EP (1) EP2245149B1 (pt)
JP (1) JP5777886B2 (pt)
KR (1) KR101588309B1 (pt)
CN (1) CN101965398B (pt)
AU (1) AU2009207302B2 (pt)
BR (1) BRPI0907469B8 (pt)
CA (1) CA2712807C (pt)
ES (1) ES2559195T3 (pt)
IL (1) IL207174A (pt)
WO (1) WO2009093189A2 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3305802B1 (en) 2015-05-26 2021-05-12 Gemvax & Kael Co., Ltd. Anti-inflammatory, anti-fibrotic and wound-healing octapeptides and compositions containing the same
BR102019018666A2 (pt) * 2019-09-09 2022-01-18 Instituto Butantan Peptídeos anti-inflamatório, composição farmacêutica compreendendo tais peptídeos e seus usos

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US20110214206A1 (en) * 1999-05-06 2011-09-01 La Rosa Thomas J Nucleic acid molecules and other molecules associated with plants
US20030211793A1 (en) 2001-03-05 2003-11-13 Eugene Bell Injectable bio-compatible material and methods of use
WO2002083856A2 (en) * 2001-04-11 2002-10-24 Bristol-Myers Squibb Company Polynucleotides encoding two novel human g-protein coupled receptors, hgprbmy28 and hgprbmy29, and splice variants thereof
BRPI0403882B8 (pt) * 2004-08-24 2021-07-27 Biolab Sanus Farmaceutica Ltda sequência nucleotídica, sequência de aminoácidos, protease ativadora de protrombina recombinante (rlopap), processo para obter a mesma na forma monomérica, uso da mesma
WO2006096426A2 (en) * 2005-03-03 2006-09-14 The Board Of Trustees Of The University Of Illinois Targeted drug delivery of pain and addiction therapies using opioid receptor-mediated internalization
BRPI0504199B8 (pt) * 2005-09-08 2021-05-25 Ana Marisa Chudzinski Tavassi composições farmacêuticas baseadas em lopap e usos das ditas composições

Also Published As

Publication number Publication date
IL207174A (en) 2015-09-24
US20110034390A1 (en) 2011-02-10
ES2559195T3 (es) 2016-02-10
JP5777886B2 (ja) 2015-09-09
EP2245149B1 (en) 2015-10-14
AU2009207302A1 (en) 2009-07-30
BRPI0907469B1 (pt) 2019-10-29
KR20100118122A (ko) 2010-11-04
IL207174A0 (en) 2010-12-30
CN101965398B (zh) 2015-03-18
US8883740B2 (en) 2014-11-11
WO2009093189A3 (en) 2009-09-17
KR101588309B1 (ko) 2016-01-25
JP2011510060A (ja) 2011-03-31
CN101965398A (zh) 2011-02-02
EP2245149A2 (en) 2010-11-03
CA2712807A1 (en) 2009-07-30
CA2712807C (en) 2019-05-21
AU2009207302B2 (en) 2015-01-22
WO2009093189A2 (en) 2009-07-30

Similar Documents

Publication Publication Date Title
BR112013018352A2 (pt) composição de minociclina tópica e método
SV2008002980A (es) Composiciones y metodos de uso para anticuerpos de dickkopf-1 y/0 -4
CL2011002943A1 (es) Anticuerpo triespecifico o tetraespecifico; metodo para la preparacion de dicho anticuerpo; celula huesped; composicion farmaceutica.
CL2011002761A1 (es) Compuestos derivados de heterociclos sustituidos, inhibidores del canal romk; composición farmacéutica; y su uso para provocar diuresis, natriuresis o ambas, hipertension, insuficiencia cardiaca, insuficiencia renal aguda y crónica y síndrome nefrótico, entre otras enfermedades.
BRPI0908637A2 (pt) composto; composição farmacêutica do mesmo e método para inibição de proliferação celular em um indivíduo.
CL2007003791A1 (es) Compuestos derivados de piperidina, inhibidores de la proteina quinasa; composicion farmaceutica que comprende a dichos compuestos; y su uso para inhibir el crecimiento celular anormal.
CO6410314A2 (es) Proteínas de unión a il-17
BR112012031071A2 (pt) 8-proteínas de ligação à il-1
CL2011002756A1 (es) Anticuerpo que se enlaza a la proteina del complemento c3b humana o de cinomolgo; composicion farmaceutica, acido nucleico, vector y celula huesped que comprenden dicho anticuerpo; uso para tratar degeneracion macular relacionada con la edad.
BRPI0819936A2 (pt) Preparação farmacêutica, método para produzir células dendríticas, células dendríticas, composição farmacêutica, e, uso de uma célula dendrítica ou uma preparação.
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
ECSP11011487A (es) Pirazinilpirazoles
BR112013017080A8 (pt) Anticorpo ou fragmento funcional do mesmo que se liga a forma ativa de calicreína do plasma humano, composiçao farmacêutica e método de detecçao de calicreína do plasma em um paciente
BRPI0809655A2 (pt) Método para tratar uma condição em um mamífero, composição farmacêutica, e, kit
CL2007001435A1 (es) Compuestos derivados de fenilalanina; proceso de prepatacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto como inhibidores de integrina para el tratamiento del cancer.
CL2008002430A1 (es) Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
BRPI0710331A2 (pt) Compostos heteroarila monocíclicos para tratamento de câncer e composição
AR066395A1 (es) Reovirus que tienen secuencias modificadas
EA201200484A1 (ru) Фармацевтическая композиция с действующими веществами - метформином и ситаглиптином или вилдаглиптином
CL2011002958A1 (es) Composición que comprende ácido 4-oxo-4-[(2-feniletil)amino]-butírico y tolclofos-metilo; y método para controlar enfermedades en plantas.
BRPI0904056A8 (pt) Composição em partículas de efusão de gás, e, método para a manufatura da mesma
UY35703A (es) Anticuerpos contra el inhibidor-1 del activador de plasminógeno (pai-1) y usos de los mismos
BR112012003800A2 (pt) composição, peptídeo, e formulação farmacêutica.
BRPI0818323A2 (pt) composição farmacêutica, uso de uma composição farmacêutica, e, método para tratar câncer.
CO2024001133A2 (es) Composiciones y métodos para la degradación selectiva de proteínas diseñadas por ingeniería

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/10/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/10/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/01/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF